Vaccines — Pipeline, Approvals, Sponsors
42
Marketed
0
Filed
3
Phase 3
2
Phase 2
17
Phase 1
69
Total
Marketed leaders
- — RESPIRATORY SYNCYTIAL VIRUS PRE-FUSION GLYCOPROTEIN F
- — SARS-COV-2 VIRUS, INACTIVATED
- — Comirnaty · Pfizer Inc. · vaccine · Infectious Disease
- — Prevnar 20 · Pfizer Inc. · Pneumococcal conjugate vaccine · Immunology
- — SARS-COV-2 VIRUS SPIKE PROTEIN
- — CHIMPANZEE ADENOVIRUS ENCODING SARS-COV-2 SPIKE GLYCOPROTEIN
- — TOZINAMERAN · Immunology
- — VARICELLA ZOSTER VIRUS ENVELOPE GLYCOPROTEIN E
- — INFLUENZA B VIRUS, INACTIVATED NEURAMINIDASE
- — HUMAN PAPILLOMAVIRUS, L1 PROTEIN VIRUS LIKE PARTICLES
- — BORDETELLA PERTUSSIS TOXIN
- — BORDETELLA PERTUSSIS FILAMENTOUS HEMAGGLUTININ
Recent approvals (last 30 days)
Upcoming PDUFA (next 180 days)
Top sponsors in this modality
- Pfizer Inc. · 40 vaccines
- Pfizer · 16 vaccines
- · 13 vaccines
Drug classes within Vaccines
- Vaccine · 7
- vaccine · 5
- mRNA vaccine · 2
- Monoclonal antibody · 1
- Not available · 1
- Not specified · 1
- PENBRAYA is a combination vaccine that protects against meningococcal serogroups A, B, C, W, and Y. · 1
- Pneumococcal conjugate vaccine · 1
- Conjugate vaccine · 1
- Trumenba is a sterile, recombinant vaccine targeting Neisseria meningitidis serogroup B. It contains · 1
- Unknown · 1
- Viral protein subunit vaccine · 1
Subscribe to ongoing alerts
Push every new vaccines event into your RSS reader:
Other modalities
BiologicsMonoclonal AntibodiesSmall MoleculesAntibody-Drug ConjugatesCell TherapiesGene TherapiesGene EditingmRNA TherapeuticssiRNA TherapeuticsAntisense OligonucleotidesBispecific Antibodies
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing